The Phase 1 clinical trial investigating the pharmacokinetics of a once daily, extended-release formulation of camlipixant is ongoing.

Source: https://www.marketscreener.com/quote/stock/BELLUS-HEALTH-INC-64752274/news/BELLUS-Health-Reports-Year-2022-Financial-Results-and-Business-Highlights-43304353/?utm_medium=RSS&utm_content=20230321

The study was conducted as a randomized, double-blind, dose-ranging, placebo-controlled to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of OC514 in 28 healthy volunteers.

Source: https://www.ibtimes.com.au/press-release/20230511/oncocross-completes-phase-i-global-clinical-trial-of-oc514-treatment-for-sarcopenia

This multi-center, open-label trial is intended to evaluate the safety, tolerability, pharmacokinetics antitumor activity and pharmacodynamics of 154 in combination with liposomal doxorubicin.

Source: https://seekingalpha.com/article/4582238-shattuck-labs-inc-sttk-q4-2022-earnings-call-transcript?source=feed_all_articles